Table 3 Outcomes stratified by Visual Acuity at presetation

Eyes, n (%)

4 (10)

12 (20)

0.05

Baseline VA logMAR, mean (SD)

0.28 (0.05)

0.18 (0.13)

0.5

Final VA logMAR, mean (SD)*

0.54 (0.83)

0.22 (0.25)

0.71

Change VA logMAR*,

mean (95% CI)

0.26

(−1.04, 1.57)

0.03

(−0.13, 0.2)

0.61

Baseline CST μm, mean (SD)

423 (152)

330 (102)

0.31

Final CST μm, mean (SD)*

268 (50)

230 (110)

0.46

Change CST μm*,

mean (95% CI)

− 155

(− 390, 80)

− 79

(− 206, 48)

0.42

Injections^α, median (Q1, Q3)

0.5 (0, 1.5)

0 (0, 1.2)

0.94

Additional Macular Laser, n

0

0

1

Additional Triamcinolone, n

0

0

1

Additional PRP, n

1

5

1

Eyes, n (%)

35 (90)

48 (80)

Baseline VA logMAR, mean (SD)

1.22 (0.57)

0.89 (0.34)

0.02

Final VA logMAR, mean (SD)*

0.97 (0.74)

0.44 (0.42)

< 0.001

Change VA logMAR*,

mean (95% CI)

−0.26

(−0.49, −0.03)

−0.44

(−0.57, − 0.32)

0.15

Baseline CST μm, mean (SD)

531 (218)

449 (153)

0.07

Final CST μm, mean (SD)*

355 (168)

291 (137)

0.12

Change CST μm*,

mean (95% CI)

− 188

(− 294, −82)

−120

(−206, −34)

0.30

Injections^α, median (Q1, Q3)

2 (1, 3)

2 (1, 3)

0.72

Additional Macular Laser, n

0

2

0.5

Additional Triamcinolone, n

2

2

1

Additional PRP/Sectoral Laser, n

15

10

0.05